Glenmark Chief: Running A Facility In The US Has Been A Struggle
Firm Primes Global Scale In Respiratory Segment
Glenmark readies scale up in the respiratory segment, with Ryaltris set for a US debut and a filing for a generic rival to Flovent anticipated. Running a facility in that market, though, is not an easy task, says the firm's leadership.
You may also be interested in...
India’s Glenmark is hoping that its proposed generic version of GlaxoSmithKline’s Flovent will benefit from a limited competition market, as it continues to plan a filing with the US Food and Drug Administration.
Hikma and Glenmark have announced the long-awaited launch of the Ryaltris nasal spray on which the two companies have partnered in the US.
Torrent is recalibrating strategy with the addition of chronic therapies from Dr Reddy’s while it folds up an unsustainable liquids business in US. The latter resulted in the company reporting a Q4 loss but a timely bonus share issue propped up investor sentiment.